TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for upsized $100M IPO
→ San Diego-based Turning Point Therapeutics has laid out terms for its IPO, planning to sell 7.4 million shares at a range of $16 to $18 a share. Renaissance Capital reports that insiders expect to take about 40% of a total of around $125 million, which would give the oncology biotech a valuation of more than $500 million. They’ll sell shares under the $TPTX symbol. The biotech is developing a pipeline of tyrosine kinase inhibitors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.